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REFEREE REPORTS
Referee #1 (Remarks to the Author): This is an interesting paper describing the mono-ubiquitylation of DNA polymerase . The E3 enzyme carrying out the ubiquitylation is identified as MULE and the sites of ubiquitylation on pol are identified. Reduction of ubiquitylation by MULE siRNA or increasing it by knocking down the MULE regulator ARF result in increasing or decreasing rates of repair of DNA damage. Finally evidence is presented to show that monoubiquitylation by MULE is the precursor to polyubiquitylation by CHIP. Taken together, the data provide a compelling story, but there are two important omissions:
(1) What is the effect of mutating K41, K61 and K81 of Pol ? When transferred into cells, the mutant construct should, if the authors' model is correct, have a longer half-life than wt pol and should be unaffected by Mule or Arf siRNA knockdown.
(2) A clear prediction of the model shown in Fig 7 is that exposure to DNA damage should result in increased levels of pol , decreased pol -Ub and an increased half-life of pol . This can be easily tested.
Minor points. Review: This is a very interesting follow-up on a previous study from Dianov and colleagues, "CHIP-mediated degradation and DNA damage-dependent stabilization regulate base excision repair proteins", where they reported that DNA polymerase beta (Polfl) and XRCC1 are ubiquitylated by the E3 ligase CHIP and targeted for proteasome-mediated degradation if not in a repair complex. In this current study, Dianov and colleagues have identified a second ubiquitin ligase (Mule) that targets Polfl. They suggest that Mule functions as an E3 ligase to mono-ubiquitylate Polfl localized in the cytoplasm on each of three amino acid residues (41, 61 and 81). In the proposed model, the nuclear protein Polfl moves to the cytoplasm by an unknown mechanism, where it is then monoubiquitylated by Mule and then poly-ubiquitylated by CHIP, leading to the proteosomal degradation of Polfl.
Many of the points and conclusions drawn from the beautiful data are well supported. However, this reviewer suggests there are some significant points that should be addressed (as detailed below by section) to improve this manuscript and provide confidence in the claims and conclusions offered by Parsons et al:
"Mule ubiquitylates Pol at lysines 41, 61 and 81" Very strong section -clearly establishing that Polfl can be modified by Mule in vitro and the sites of in vitro ubiquitinylation are K41, K61 and K81.
"Pol ubiquitylation in living cells" This section is lacking a few important controls:
1) Is FLAG-Polfl, when purified from HeLa cells by IP (e.g., Flag-agarose) also modified in vivo by ubiquitin? This would be a more convincing result than that shown. The data shown in Figure 3C could be explained by co-purification of both Polfl and a modified protein of unknown identity.
2) The authors should also consider the reverse experiment, to IP (Pull-down) ubiquitin-modified proteins using either antibodies or other reagents and then analyze for the presence of Polfl in the pull-down population.
"In vivo ubiquitylation of Pol is dependent on Mule and ARF" The mechanism suggested in the last lines of this section implies that Polfl is in the cytoplasm and is then modified by Mule. However, Polfl is well documented as a nuclear protein and only a nuclear protein. How does Polfl get into the cytoplasm for this modification step? Is the newly synthesized peptide modified directly or is there a shuttling of Polfl from the nucleus to the cytoplasm? This should at least be discussed, if not investigated.
"ARF and Mule modulate base excision repair" Re - Figure 4A If the model is correct and ubiquitylation leads to Polfl degradation, then changes in PolflUb should reflect changes in the steady-state level of Polfl in the nucleus, This is suggested in Figure 4A where the authors indicate they observe a 1.8-fold increase in Polfl (assuming the comparison is between the Lipofectamine-nuclear blot and the siRNA-nuclear blot). However, the Lipofectaminecytoplasm blot and the siRNA-cytoplasm blot also looks like there is a 1.8-fold increase in the siRNA lane. Can the authors provide the quantification for all 4 bands? Were the intensities of the cytoplasmic PolflUb and nuclear Polfl normalized to tubulin and Fibrillarin, respectively?
Re - Figure 4D , E and Figure 5B How was it determined that (+) Mule siRNA is statistically different than (-) Mule siRNA? Please describe the analysis since it appears that the difference betweem (+) and (-) Mule siRNA in the HeLa, WI38 and WT MEFs is too small to be statistically significant.
"CHIP-dependent degradation of monoubiquitylated Pol " A critical experiment is missing that is required to formally link CHIP and MULE/ARF with regard to Polfl stability: Transfection with both Mule and CHIP siRNA. If Mule-mediated modification of Polfl is required for CHIP-mediated poly-ubiquitylation of Polfl, then this experiment (transfection +/-Mule & CHIP siRNA together and analysis of Polfl nuclear steady-state levels by immunoblot) is needed to prove this connection.
Minor Editorial Note Extra parentheses surround some references on pages 8 and 11. We would like to thank you and the reviewers' for comments on our manuscript (EMBOJ-2009-70868) . We have performed additional experiments, as suggested by the reviewer's, which has allowed us to significantly improve our manuscript. Below is our point-by-point response to the reviewer's comments for your convenience.
Referee #1 suggested two experiments: 1. The reviewer suggested to investigate the effect of mutating K41, K61 and K81 of Pol β and pointed that the mutated protein should be more stable than wild type protein.
We have constructed mammalian expression plasmids encoding either wild type or K41, 61, 81 triple mutant and found that the mutant protein is more stable than the wild type protein when expressed in HeLa cells, as predicted. These data are now added to Figure 2 and described in the text.
2. The reviewer suggested testing experimentally the effect of cell exposure to DNA damage and proposed that it should result in increased levels of Pol β, decreased Pol β-Ub and an increased halflife of Pol β.
These predictions would be absolutely correct if the mechanism we described in our manuscript would be involved in the DNA damage stress response. Such a response is mainly induced by mutagen treatment generating massive (compare to endogenous) DNA damage and, if this exists, it will require immediate changes in protein levels and their stability. The regulatory mechanism described in our manuscript is a tuning mechanism that adjusts the amount of Pol β to the small changes in endogenous DNA damage. This mechanism provides fine tuning of the amount of Pol β to the dynamically changing amounts of endogenous DNA lesions and is responsible for maintaining steady state levels of DNA repair enzymes. Hydrogen peroxide treatment used in our experiments was only an experimental approach to demonstrate that Pol β that accumulated in Muleknockdown cells increased DNA repair capacity of these cells. Pol β levels did not change instantly as a result of hydrogen peroxide treatment, instead Pol β was gradually accumulating over a 72 h period during Mule knockdown. We have previously studied the effect of hydrogen peroxide on abundance and distribution of Pol β and found that in response to extensive DNA damage, more Pol β is associated with chromatin although the amounts of Pol β do not change significantly within the timeframe needed for cells to accomplish DNA repair (about 2 h; Parsons et al. Mol Cell, 2008) . We also previously investigated how cells that can't timely increase the amount of DNA repair enzymes are coping with exogenous mutagens that induce substantial amounts of DNA lesions, and found an important role for PARP-1 in this process (Woodhouse et al. DNA repair, 2008) . We realise that the original submitted manuscript did not address this issue in depth, so we made a number of addition/changes to the Results and Discussion sections to make it clear that the mechanism that we are proposing is not a DNA damage stress response but rather a mechanism for controlling steady state levels of base excision repair proteins that is important for genome stability.
Minor points raised by the reviewer #1: Figure S1A is now corrected as suggested by the reviewer.
We have now highlighted on Figure 3A which is band is ubiquitylated Pol β and also shortened Figure 3C , as suggested by the reviewer, that demonstrates cross reactivity of the peak fraction to both ubiquitin and Pol β antibodies. Figure S3 is now corrected as suggested by the reviewer. Figure 3D . The reviewer asked how many times the experiment was reproduced and suggested to quantify the data and correct the statement on Pol β ubiquitylation by Mule (page 8).
All the experiments presented in this manuscript were reproduced at least 3-5 times and a sentence containing quantification and indicating the amount of experiments is now added. The sentence on Pol β ubiquitylation by Mule (page 8) has now been changed as suggested by the reviewer.
Page 13. First sentence, that was not clear, has now been removed.
Reviewer #2
1. The reviewer suggested demonstrating ubiquitylation of Flag-Pol β after transfection and IP. We performed this experiment that demonstrates that Flag-Pol β is ubiquitylated and the data are now included in Figure 3D .
2. The reviewer comment: "The mechanism suggested in the last lines of this section implies that Pol β is in the cytoplasm and is then modified by Mule. However, Pol β is well documented as a nuclear protein and only a nuclear protein. How does Pol β get into the cytoplasm for this modification step? Is the newly synthesized peptide modified directly or is there a shuttling of Pol β from the nucleus to the cytoplasm?
We would not disagree with the reviewer that Pol β is mainly a nuclear protein. However, in HeLa cells we consistently find a small amount of Pol β (about 15-20%) in the cytoplasm. This is actually the proportion of Pol β that is a subject for ubiquitylation by Mule, which is entirely cytoplasmic, and targeted for degradation. This is also the fraction of Pol β that can be translocated into the nucleus if ARF signals that more Pol β is required by inhibiting Mule. To address this reviewer comment and to present our model better, we have now replaced Figure 7 with a more detailed scheme. We have also added more discussion of this model in the Discussion section.
3. Re: Figure 4A . The reviewer suggested that "if the model is correct and ubiquitylation leads to Pol β degradation, then changes in Pol β-Ub should reflect changes in the steady-state level of Pol β in the nucleus, This is suggested in Figure 4A where the authors indicate they observe a 1.8-fold increase in Pol β (assuming the comparison is between the Lipofectamine-nuclear blot and the siRNA-nuclear blot). However, the Lipofectamine-cytoplasm blot and the siRNA-cytoplasm blot also looks like there is a 1.8-fold increase in the siRNA lane."
The reviewer is absolutely right. The amount of Pol β was increased in both the cytoplasm and the nucleus after Mule knockdown. This is because Pol β should originally accumulate in the cytoplasm and later relocate to the nucleus for DNA repair. The reason why we did not mention changes in the cytoplasmic fraction is because only nuclear Pol β is a major contributor to DNA repair. We have now mentioned the cytoplasmic Pol β increase in the text to address this issue.
The reviewer also suggested to provide the quantitation for bands in Fig. 4A and normalized them to Tubulin and Fibrillarin.
We include quantitation of the bands in to the text and we should also note that in all our experiments the amount of proteins was normalised to the corresponding loading control. 4. Re: Figure 4D , E and Figure 5B . The reviewer suggested describing statistical analysis of Figures 4D, E and 5B.
All the requested data are now added in the revised manuscript that demonstrates a statistically significant difference (by Student's t-test) in repair kinetics between Lipofectamine and Mule/ARF siRNA.
5. The reviewer suggested analysing Pol β stability after simultaneous knockdown of Mule and CHIP.
This experiment is now added as Figure 6C that fully supports our previous findings and conclusions.
Re-Review 23 July 2009
The manuscript was reassessed by one of the original referees. There were no further comments.
